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IMMOBILIZATION OF HIRUDIN ON SURFACE OF PTFE TO INCREASE 
ITS  BLOOD COMPATIBILITY    
SUMMARY 
Blood compatibility is an essential feature for blood-contacting biomaterials, namely 
blood vessel grafts, artificial heart and catheters. Surface induced thrombosis is one 
of the major causes for the failure of these biomaterials and can be minimized by 
altering the surface characteristics. 
The aim of this study is to increase the blood compatibility of 
polytetrafluoroethylene (PTFE), one of the preferred materials for this kind of 
applications, by a two-step procedure: Firstly, the surface was activated by hydrogen 
plasma followed by acrylamide attachment and secondly, hirudin, a potent 
antithrombogenic protein from leeches, was immobilized to the surface. The first part 
of the study involving the plasma treatment was optimized and different surfaces 
were characterized by water contact angle measurements and ATR-FTIR. It was seen 
that the contact angle of the PTFE was decreased from 130 ̊ to 59 ̊ by optimizing the 
hydrogen plasma treatment conditions. Then acrylamide solution (25 % w/v; in 
ethanol/acetone (50 % v/v)) was applied to the surface and subjected to argon plasma 
treatment (1 min-50 W-13 Pa) for monomer grafting. Water contact angle was 
further down to 33 ̊ and amide groups can be detected by ATR-FTIR analysis. In the 
second part, hirudin was attached to amide groups on   PTFE surface by EDC/NHS 
activation. Then thrombogenicity (Kinetic Model) test was applied to detect hirudin 
activity. Test results showed that there is a serious decrease in the clot formation 
compared with the pristine PTFE samples. Even no clot formation observed in some 
cases.    
As a result, we increased blood compatibility of PTFE surfaces by plasma-induced 
monomer grafting and hirudin immobilization and obtained an alternative material to 
be used in medical applications such as vascular graft, catheters etc.    
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PTFE  YÜZEYLERE KAN UYUMLULUĞUNUN ARTTIRILMASI İÇİN  
HİRUDİN TUTUKLANMASI 
ÖZET 
Kan uyumluluğu yapay  kan damarı, yapay kalpler ve kateterler gibi kan ile temas 
eden biyolojik malzemeler için gerekli bir özelliktir. Biyolojik malzemelerin 
yüzeylerinde oluşan pıhtılaşma bu malzemelerin kullanımlarını engelleyen en önemli 
faktörlerden birisidir. Malzemelerin yüzeylerinde yapılacak olan değişiklikler ile bu 
problem büyük oranda çözülebilmektedir.  
Bu çalışmanın amacı biyomalzeme olarak kullanılabilen PTFE yüzeylerin, önce 
hidrojen plazma ile aktif hale getirilmesi, daha sonrada akrilamit monomerlerinin ve 
sülüklerden izole edilen ve pıhtılaşmayı engelleyen bir enzim olan hirudinin yüzeye 
tutuklanmasıdır. Çalışmanın ilk kısmında, farklı PTFE yüzeylerinde temas açısı 
ölçümleri ve ATR-FTIR analizleri yapılarak plazma uygulaması için en uygun 
koşullar belirlendi. Hidrojen plazma koşullarında yapılan optimizasyon ile PTFE 
yüzeylerin temas açısı 130 ̊ den 59 ̊ kadar düşürülmüştür. Daha sonra, yüzeylere önce 
akrilamit çözeltisi  ( %25 w/v; etanol/aseton ( %50 v/v)) , sonrada monomer 
aşılaması için (1 dk-50 W-13 Pa) Argon plazma uygulanmıştır.Yapılan temas açısı 
ölçümlerinde açısının 33 ̊ kadar düştüğü, ATR-FTIR analizlerinde ise  1665 cm-1 
civarında amid gruplarının varlığı görülmüştür. Çalışmanın ikinci kısmında 
EDC/NHS aktivasyonu ile hirudin yüzeydeki amide gruplarına bağlanmıştır. Daha 
sonra trombus oluşumu (Kinetik Model) testi uygulanarak hirudinin aktivitesi 
ölçülmeye çalışıldı. Sonuçlar normal PTFE yüzeyleri ile karşılaştırıldığında 
pıhtılaşmada ciddi bir azalmanın olduğu, hatta bazı ölçümlerde neredeyse hiç 
pıhtılaşma olmadığını gözlenmiştir.   
Sonuç olarak, plazma yöntemine dayalı monomer aşılama ve hirudin tutuklama 
yöntemiyle PTFE malzemenin yüzeyinin kan uyumluluğunu arttırmayı başardık ve  
yapay kan damarı, kateter vb. gibi medikal uygulamalarda kullanılabilecek biyo 
malzemelere bir alternatif elde ettik.   
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1.INTRODUCTION 
Biomaterials research is dedicated to increase the quality and duration of human life 
by assisting to restore the damaged and non-functional body parts. An important 
feature of this field is that it requires a multidisciplinary effort to obtain effective 
results. Since different kinds of materials like metals, ceramics, polymers or 
composites can be used depending on necessity, good knowledge of materials’ 
properties, how to manipulate and process them, how to characterize them is 
extremely important. Scientist from life sciences, on the other hand, should be able to 
define what kind of properties is needed for a specific biomaterial and then involve 
in the protein/enzyme immobilization, optimization, activity measurements, and so 
on. Only with this kind of collective effort, a biomaterial of medical value can be 
designed. 
When biomaterial and the body come into contact, the material should be stable and 
should not release any toxic, carcinogenic or teratogenic substances into the body 
which result in adverse effects. Furthermore, blood compatibility is very important 
for blood-contacting biomaterials. Surface induced thrombosis is one of the major 
causes for the failure of these biomaterials and altering their surface characteristics 
while preserving the bulk properties is an effective way of increasing their 
performance. 
Our aim is to increase blood compatibility of PTFE surfaces to use them in medical 
applications. To do that, we generated functional groups (amides) on PTFE surfaces 
for hirudin immobilization by plasma induced grafting and optimized plasma 
conditions for H2 and Ar plasma. Surface characterization of plasma treated PTFE 
samples was done by water contact angle measurements and ATR-FTIR analysis to 
check plasma effect. Finally, hirudin was immobilized onto the created functional 
groups (amides) by using EDC/NHS technique, and finally, activity of immobilized 
hirudin was tested by using thrombogenicity (Kinetic model) assay. 
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2.1 Biomaterials 
2.1.1 Definition of biomaterials 
Biomaterials  are synthetic or natural materials that are used in medical devices or in 
contact with biological systems  to treat damaged tissues or organs to restore their 
functions, or used to replace them.  Biomaterials have wide range of applications 
both medical and nonmedical fields (Table 2.1). 
    Table 2.1: Uses for biomaterials [1] 
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2.1.2 History of biomaterials 
Biomaterials have being used for along time in our life. Their usage dates far back 
into ancient times. Artificial eyes, ears, teeth and noses were found in Egypt 
mummies [2]. However, the early medical implants were destined to fail because 
people did not have enough information about the concepts related to infection, 
materials, and the biological reaction to materials. For some scientists, the modern 
era of medical implants started at 1940 when British ophthalmologist Harold Ridley 
had an observation on the Spitfire fighter pilots and developed first implantation lens 
in 1949. Following this discovery, Harold Ridley worked on intraocular lenses 
(IOLs), Charnley developed the hip implant, Vorhees invented the vascular graft, 
Kolff was revolutionizing kidney dialysis, and Hufnagel invented the ball and cage 
heart valve and they all became pioneer of medical biomaterials [1]. 
 
2. 1.3 Features of biomaterials  
There are several requirements for a material to be used for medical applications. 
First of all, they should have appropriate mechanical properties to fit its application. 
A hard tissue implant such as knee joint for example, should not deteriorate or 
corroded in the body, and withstand the fatigue. A skin implant, on the other hand, 
should be elastic. Then, they should be sterilized (by autoclave, ethylene oxide, or γ-
ray) without degradation. When materials come into contact with a living organism, 
there are interactions between the biomaterial and a biologically or chemically active, 
fluid-based medium, so biomaterials and their degradation products can damage cells, 
cause cancers, or lead to blood clotting. To handle these drawbacks, the materials 
should be biocompatible that is it should not produce a toxic, injurious, or 
immunological response in living tissue. Furthermore, size, shape, and porosity 
properties should be controlled. For example, for the cardiovascular implants, 
devices should have certain size to avoid clotting, and drug permeability and good 
release properties for drug delivery are needed [3]. 
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2. 1.4 Types of biomaterials 
Biomaterials that are used in medical field can be grouped into four classes 
depending on their structural and mechanical properties such as metals (Gold, 
tantalum, stainless steel, Co-Cr, NITI, Ti alloys), ceramics (Alumina, titania, zirconia 
bioglass, carbon, hydroxyapatite), polymers (Polyethylene(PE),polyurethane(PU), 
polytetraflouroethylene   (PTFE), poly acetal (PA) ) , and composites (HA/PE, 
silica/SR, carbonfiber/ultra high molecular weight ). Although metals have high 
strength, ductility and resistance to wear, they have some limitations such as low 
biocompatibility, corrosion, high stiffness compared to the tissues and they can 
release ions that may cause allergic tissue reactions [4]. Ceramics have good 
biocompatibility, and they are resistant to corrosion and high compression, but 
brittleness, low mechanical reliability, difficulties in manufacturing, and inelasticity 
are some of the drawbacks of ceramics. Metals and ceramics are generally used in 
hard tissue applications (dental applications, bone plates, joint replacement, knee 
replacement, etc.) because of their structural and mechanical properties. To handle 
the drawbacks of metals and ceramics, composites materials are developed by using 
different combinations of metals, ceramics and polymers. Polymers are generally 
preferred in soft tissue applications (wound dressing, catheters, vascular graft etc.) 
[2]. Since polytetrafluoroethylene  (PTFE)  is a polymer and the  material used in this 
study, more emphasis given on polymers as biomaterials in  section 2.2. 
2.2. Polymers As Biomaterials 
2.2.1 Polymers and their medical applications 
Polymers commonly used in biomedical devices may be classified in two categories 
as natural polymers and synthetic polymers depending on their origins. Enzymes, 
nucleic acids, proteins, cellulose and natural rubber are examples of natural polymers. 
There are also a large number of synthetic (man-made) polymers consisting of fibers, 
elastomers, plastics, adhesives, etc. These natural and synthetic polymers have a 
wide range of application fields in medical area such as extracorporal blood-
circulating devices, catheters, blood bags and tubing used for blood transfusion, 
membranes, hollow fibers, and tubing used for dialysis devices etc. In Table 2.2, 
Polymers and their medical applications are given.  
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 Table 2.2: Polymers in Medical Applications [5] 
 
 
 
 
2. 2.2 Polymers used in blood-contacting biomaterials 
Polymers that are used in cardiovascular applications have a wide range of variety. 
Devices that are made of with polymers and contacting with blood in cardiovascular 
applications are grouped into three categories such as devices that are used for 
permanent replacement in the circulatory system (artificial hearth, hearth valves, 
vascular grafts); devices that are inserted into a blood vessel for varying time periods 
of time (catheters, sensors, imaging agents etc.); and extracorporeal devices that are 
used for removal or return of blood from body ( blood oxygenators, hemodialysis 
units ( artificial kidney), etc. ). In Table 2.3, blood contacting polymers and 
applications in devices are given. 
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Table 2.3: Blood Contacting Polymers [6] 
 
 
 
Some artificial hearth devices uses a special balloon dilation catheter made of 
polyvinylchloride (PVC) or polyethylene (PE) [7]. In addition, blood pumps of sac or 
diaphragm type are made from PVC, polyolefin rubber (Hexsyn), silicone rubber 
(Silastic), and polyurethane (PU) such as Avcothane, Biomer, and Pellethane are 
reported [8-10]. 
 
Mechanical valves and bioprosthetic heart valves are two kinds of commonly used 
heart valve prostheses. Polymer valves are generally preferred for temporary 
replacement. The polymers used in mechanical valves are a Dacron or 
poly(tetrafluorethylene) (PTFE), and a poly(ethylene terephtahalate)-covered stent 
for bioprosthetic hearth valves[7]. Polymer valves such as seamless trileaflet valves 
have been made of PUs [11]. 
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Vascular grafts that are made of polymeric materials are among the most successful 
artificial organs and frequently used in permanent implantations. Vascular grafts 
whose diameter is >6 mm is generally used in medical applications, because vascular 
grafts whose diameter is <4 mm have a possibility to form thrombus. To handle this 
drawback, scientists have been working on modification of the surface biomaterial. 
The polymers most often used are polyester (Dacron) fiber in woven, knitted, and 
velour types, or porous expanded PTFE (Telfon, Gore-Tex, Impra) fabrics [12-
13].Their porous structure induces the formation of new pseudoneointima, resulting 
in the prevention of blood leakage.  
 
When myocardial activity or electrical conducting pathways of a hearth is 
dysfunctional or unreliable, cardiac pacemakers are used to supply electrical 
stimulation to the heart to store its function again. Silicone and PUs such as 
Pellethane are used in the wire lead insulation of pacemakers because of their blood 
compatibility and durability [14]. 
 
Blood oxygenators, are used as extracorporeal heart–lung machines, to replace the 
heart temporarily in open-heart operations. There are two types of blood oxygenators, 
the bubble type and the membrane type. The former, in which blood is directly 
contacted with oxygen and carbon dioxide, is composed of soft plasticized PVC film 
or rigid polycarbonate (PC); in the latter blood is oxygenated via a polymeric 
membrane such as PP, silicone rubber, PTFE, or polysulfone [7].  
 
There are many different kinds of intravascular catheters. For intravenous (IV)-
administration indwelling catheters PE, PP, silicone rubber, and PU are used. Other 
types of catheters made of PU, PVC or Teflon-coated Dacron are also reported [7]. 
Balloon-tipped catheters are another type of catheters and used to monitor blood 
pressure. 
 
2.2.3 Polytetrafluoroethylene (PTFE) 
Polytetrafluoroethylene (PTFE) was discovered by R. Plunkett in 1938 [15]. The 
molecular structure consists of carbon chain in center covered by fluorine sheath to 
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protect carbon chains from chemical attacks by forming a helix around carbon atoms 
(Figure 2.1) [16]. 
 
 
                                                                       
     Figure 2.1: Polytetrafluoroethylene (PTFE) structure a) linear form, b) 3-D form 
 
 
Since C-F bonds are very stable, the polymer has a high stability even when it is 
heated above its melting point. Its’ melting point changes between 300- 380 ̊ [17], 
and its density is ca 2.13-2.19 g/cm3. PTFE has a high chemical resistance and 
insoluble in all organic solvents except in some certain fluorinated liquids such as 
perfluorinated kerosenes at temperatures approaching the melting point of the 
polymer, and incapability of specific interactions because of high crystallinity 
(>90%). Furthermore, PTFE is a tough, flexible material of moderate tensile strength 
(2500–3800 psi, i.e., 17–21 MPa) at 238C. The friction coefficient of PTFE is low 
and is about 0.07. In literature, coefficient of friction is reposted to be in the range of 
0.02-0.10 for polymer to polymer, and 0.09-0.12 for polymer to metal [5]. PTFE has 
also weathering resistance, so it is not wetted by water or has a very low adsorption 
(0.005%) [5] and high dielectric strength, low dielectric constant. All these and other 
properties of polytetrafluoroethylene were given in details by Sperati [18].   
PTFE seems a good polymer for medical applications because of its properties such 
as low coefficient of friction, hardness, high thermal stability, and chemical 
resistance, but its biocompatibility should be improved to be used in cardiovascular 
applications to avoid thrombus formation on the surface.  
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2.3. Biocompatibility and Material-Blood Interactions 
 
2.3.1 Biocompatibility 
 
When materials come into contact with a living organism, there are interactions 
between the material and a biologically or chemically active, fluid-based medium, 
and if the material is not biocompatible, the material itself, its degradation products 
or additives can damage cells, cause cancers, or lead to blood clotting. Therefore, 
biocompatibility may be defined as the ability of a material to perform with 
appropriate host response in a  
specific application without adversely and significantly affecting the body and, 
without the material itself suffering any adverse effects [19,20]. When the material is 
integrated into the body, it should not induce thrombus formation, immune response, 
inflammatory reaction, or infection; and it must be nontoxic, noncarcinogenic, and 
nonmutagenic [21]. Materials contacting the blood and not inducing thrombus 
formation, inflammatory reaction or infection, and nontoxic as mentioned before is 
called as blood compatible that is one of the specific definition of biocompatibility. If 
the material is used as a tissue replacement then it should be tissue compatible which 
is another specific definition of the biocompatibility. Blood compatibility is also one 
of the most important properties of biomedical polymers.   
 
2.3.2 Material-Blood interactions 
 
2.3.2.1 Blood clotting mechanism 
 
Blood is composed of three main elements such as liquid medium, plasma, and 
cellular elements, which are subdivided into red blood cells (erythrocytes), white 
blood cells (leukocytes), and platelets. When the material comes into contact with 
blood, first event occurs between material and blood is redistribution of interfacially 
bound water and ions, and rapid adsorption of plasma proteins. These processes 
influence subsequent interactions of blood cells, especially platelets and leukocytes, 
with proteinated surfaces.  
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Adsorption of plasma results in activation of blood coagulation cascade. Activation 
of blood coagulation cascade leads to the polymerization and crosslinking of fibrin at 
the blood interface. There are different coagulation pathways that are initiated by 
absorbed proteins depending on the nature of the surface. The overall scheme of 
blood coagulation is summarized in Figure 2.2.  
 
 
 
Figure 2.2: Thrombus formation on the material surfaces [7]  
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There are two types of plasma protein adsorption at the blood–material interaction as 
seen in Figure 2. 2. The first one is adsorption of albumin, fibrinogen, or γ-globulin 
from the blood plasma, and the second one is platelet and leukocyte adhesion which  
result in the polymerization of fibrin onto the surface. 
Platelet ahdesion/activation 
Platelets are small disc-type elements containing a variety of granules. Platelets 
adhere to materials through pseudopodia, some internal changes occur in the platelets, 
which result in releasing granules. Released granules attract more platelets and 
attracted platelets start to stick each other. This is called as platelet aggregation. This 
platelet aggregation then result in initiating thrombus. Adenonsine diphosphate 
(ADP), and thromboxane A2 are the two most important released components which 
are very effective and potent substance for platelet aggregation. 
Activation of coagulation factors 
Activation of blood coagulation factors is another coagulation pathway. Enzymes, 
lipids and ions are needed to activate blood coagulation factors and to form fibrin. 
Thrombin that is the main coagulation factor polymerizes the soluble fibrinogen 
monomer into an insoluble crosslinked fibrin network. Actually, fibrin is formed in 
response to three independent mechanisms such as platelet adhesion and activation 
like mentioned before and extrinsic pathways, or intrinsic pathways of coagulation 
factor activation like in Figure 2.3. The extrinsic pathway is activated by blood 
exposed to tissue factors (collagen, membrane constituents, lipids, and proteins). In 
the intrinsic pathway, blood is exposed to artificial surfaces, where various 
coagulation factors are adsorbed and converted in a chain reaction. The intrinsic and 
extrinsic pathways differ in initiation mechanism, but stimulate thrombin the same 
way. The activation of coagulation factors involves platelet phospholipids and Ca2+ 
ions. 
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Figure 2.3: Coagulation Pathways [6] 
 
Complements and fibronectins 
In addition to plasma proteins, platelets, and coagulations factors, there are two 
additional factors affect blood compatibility of biomaterials known as complements 
and fibronectins. Complements are the primary humoral mediator of antigen–
antibody 
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reactions, and therefore are related to immunity. If complements are activated, 
leukocytes will adhere to artificial surfaces. These leukocytes and activated 
complements may also attract platelets and help in the formation of mural thrombus. 
Fibronectins are glycoproteins found on the surface of various cells and present in 
platelet granules. Fibronectins act as adhesive proteins to bind cells to other cells and 
artificial substrates. They have affinity for fibrinogen, fibrin, and platelets. 
Fibronectins also appear to be important in mural thrombus. 
2.4. How to Prevent Clot Formation 
2.4.1 Immune system 
Since biomaterials contact with the biologically or chemically active, fluid-based 
medium in the body, coagulation must be prevented. Otherwise, people come across 
with serious health problems, even they may pass away. The body has a defense 
system against coagulation that result in disruption in system functions. If any 
coagulation attempt exists, immune system becomes active. Then, fibrinolytic 
enzyme plasmin and its proenzyme, plasminogen which are in charge to dissolve 
fibrin in the body, start to dissolve fibrin. 
2.4.2 Anticoagulants  
Anticoagulants such as Antithrombin III, Heparin, Prostaglandins,hirudin, urokinase 
and several drugs like Aspirin and dipyridamole also prevent formation of fibrin by 
inhibiting steps that are shown in Figure 2.4. Antithrombin III is a lipoprotein in the 
body, and the most potent inhibitor of coagulation. Heparin is a carbohydrate that 
contains sulfate and sulfonate groups, and functions as an anticoagulant by binding to 
and activating antithrombin to inhibit thrombin. Prostaglandins are long-chain 
hydroxyunsaturated fatty acids, and also prevent platelet aggregation, so clot 
initiation does not start. Drugs such as aspirin and dipyridamole also act as 
anticoagulants, and inhibit platelet aggregation. 
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Figure 2.4: Anticoagulation Pathways 
Biomaterials should be biocompatible as mentioned until now, so coagulation must 
be prevented on the material surface by anticoagulants. To make a material blood 
compatible, variety of surface modification techniques have been studying to create 
useful surfaces to immobilize anticoagulants such as heparin, urokinase and hirudin..  
15 
 
2.5. Surface Modification Techniques for Polymers 
 
2.5.1 Chemical modification of polymer surfaces 
 
Surface modifications should not affect the bulk properties of polymers very much, 
but create surfaces with desired properties. The chemical treatment of polymers for 
surface modification includes reactions as oxidation, halogenation, and other 
standard chemical reactions. 
 
Surface oxidation techniques include the use of corona discharge, ozone, hydrogen 
peroxide, nitrous acid, alkaline hypochloride, UV irradiation, oxidizing flame, and 
chromic acid. The reactions result in initiation of the formation of hydroperoxides, 
that catalyze the formation of aldehydes and ketones and then, acids and esters. If 
surface-oxidized polyethylene coated with a thin film that is produced by using, 
vinylidene chloride, acrylonitrile, and acrylic acid terpolymers becomes impermeable 
to oxygen and more resistant to grease, oil, abrasion, and high temperatures[5] . 
Alkali and acid treatments is another chemical method used for surface modification 
of polymers. When alkali and acid treatments applied to the polymers, containers 
suitable for storing light-sensitive compounds, improved adhesion to polyethylene 
and nylons, antifogging lenses can be produced. Surface halogenation also result in 
increased adhesion to polar surfaces [5].  
 
2.5.2 Surface modification of polymers by grafting 
 
Modified polymers surfaces can also be created by grafting [22]. There are two 
methods for producing grafted polymer surfaces: direct coupling of existing polymer 
molecules to the surface and graft polymerization of monomers to the surface 
 
2.5.2.1 Polymer coupling 
In polymer coupling, polymers are directly used for surface modifications in stead of 
monomers to obtain functional groups. Two theories exist to graft a polymer to a 
surface 
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for blood contacting polymers. First theory, grafting a hydrophilic polymer to the 
target surface in order to separate blood proteins [23-25]. Then second theory is to 
confer the biological properties of the grafted macromolecule (for example heparin) 
to the surface [26]. 
 
2.5.2.2 Graft polymerization 
 
Graft polymerization involves the radical polymerization of acrylic or vinylic 
monomers onto the polymeric surface, and then producing peroxides by using these 
monomers. There are different kinds of methods used for graft polymerization onto 
different substrate surfaces such as direct chemical modification [27], ozone [28,29], 
gamma rays [30], electron beams [31], glow discharge (low temperature plasma) [32-
34], corona discharge [35-36], and UV irradiation [37]. 
 
2.6. Plasma and Plasma Treatment 
 
2.6.1 Plasma 
 
Plasma is a quasi-neutral gas and known as fourth state of matter. It includes both 
electrons and ions as well as neutrals, atomic and molecular species that occur 
because of presence of an electromagnetic field. Plasma mainly generated by electric 
field, but magnetic field, combustion and nuclear reactions can also generate plasma.  
Different kinds of reactions happen in plasma such as excitation, ionization and 
dissociation. The excitation means increasing internal energy and translation to a 
higher state. If the energy is given more than required that is enough for excitation, 
electrons that are weekly bounded are removed form an atom and result in ionization. 
Excitation and ionization can also occur because of the reactions by electron 
collision, ion collision, neutral particle collision and radiation. Dissociation occurs as 
a result of inelastic collision of a molecule with an electron, ion or photon. When 
neutral fragments, either hot or in an excited state, hit the substrate surface they 
affect the process chemistry.  
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As an example; the various active species generated in a CCP reactor are shown in 
Figure 2.5 [38]. 
 
 
Figure 2.5: Schematic diagram of capacitatively coupled reactor 
 
2.6.2 Plasma sources 
 
There is a variety of plasma sources that can be grouped into 3 main categories such 
as gaseous, metallic, and laser-based plasma sources (Table 2.4) [39].  
 
Table 2.4: Plasma Sources 
1. Gaseous plasma sources        
 -Radio frequency (RF) glow discharge                          
 -Electron cyclotron resonance (ECR)     
 -Corona discharge atmospheric arc  
2. Vacuum arc plasma source 
 
3. Laser plasma source 
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In our study, RF glow discharge plasma source is used for the surface modification 
of PTFE, so the characteristics of this plasma source, such as the electron 
temperature, ion temperature, electron density, and uniformity will be discussed 
more than other techniques in the next section.  
 
2.6.2.1 Gaseous plasma sources 
 
RF glow discharge plasma source 
 
RF glow discharge plasma is a gaseous plasma, and gaseous plasma is ignited by 
applying a potential through the gas, and the breakdown potential that depends on the 
pressure and discharge gap width. For example, the relationship between the 
breakdown potential of air and pressure is given in Figure 2.6.  
 
 
                    
Figure 2.6: Breakdown potential versus pressure and discharge gap [39] 
 
A change in this value leads to an increase of the critical breakdown electric field. 
There are four regions between the current and voltage in a low-pressure gas 
discharge such as (1) dark or Townsend discharge, (2) normal glow, (3) abnormal 
glow, and (4) arc discharge where the plasma becomes highly conductive like in 
Figure 2.7. 
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Figure 2.7: Current–voltage characteristics of a low-pressure gas discharge at 1 Torr [39] 
 
Plasma sources such as direct current (DC), RF glow discharge (rfGD), and electron 
cyclotron resonance (ECR) are operated at low-pressure as the breakdown electric 
field is smaller and the current is more controllable. These plasma sources can 
generate large area uniform plasma with a well controlled electron density. 
 
RF is able to produce a large volume of stable plasma, so it is often chosen as a 
source for Plasma Surface Modification (PSM). The RF discharges can be grouped 
as  capacitive coupling and inductive coupling based on RF power. Plasma produced 
with capacitive coupling called as capacitively coupled plasma (CCP) and 
inductively coupled plasma (ICP) if it is produced with inductive coupling. In the 
ICP reactor, a magnetic field is created around the coil where passing electric current 
generates plasma. Since the electrodes are kept outside the reaction chamber (Figure 
2.8), ICP reactors are free from contaminants such as impurities introduced to the 
plasma process [39]. 
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Figure 2.8: Schematic diagram of inductively coupled reactor  
 
In the CCP reactor, one of the two metal electrodes is connected to the power supply 
and the other one is grounded like in Figure 2.5. 
 
13.56 MHz is generally used in RF glow discharge and the pressure during discharge 
changes between 10-3 and 100 Torr [40,41]. The electron density in RF glow 
discharge in low-pressure (10-3 to 1 Torr) varies from 109 to 1011 cm-3, whereas the 
electron density in medium pressure (1–100 Torr) can reach 1012 cm-3 [42]. The 
electron temperature is several eV and the ion temperature is very low [39].  
 
Electron cyclotron resonance (ECR)  
 
ECR plasma source is operated at a pressure between 10-5 and 10-3 Torr  which 
means plasma is generated at low pressure. To produce ECR plasma, Microwave 
power at 2.45 GHz is used. To achieve the ECR conditions, there are coils occur 
around chamber to supply magnetic field. When electrons come into contact with the 
magnetic field, they start to rotate around the magnetic field lines. To obtain a high 
density plasma, magnetic field should be adjusted to match the cyclotron frequency 
of the electrons.  
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Corona discharge 
 
Corona discharge produces corona effect which mean formation of high energy 
electromagnetic fields close to charged thin wires or points. Corona discharge system 
contains two electrodes whose sizes are different from each other like in Figure 2.9 
[38]. 
                               
Figure 2.9: Corona Discharge Plasma System 
 
Anode has a small characteristic compared to cathode and strong electric field 
because of high voltage. The material to be treated is placed on the cathode and the 
discharge is usually carried out in atmospheric air. 
 
Atmospheric arc 
 
Plasma spray torch is commonly used atmospheric arc plasma. The schematic of a 
plasma spray torch is given in Figure 2.10. It consists of an outer grounded and 
water-
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cooled shield as an anode, and gas inlet components and sticky-type cathode with a 
conical tip. To obtain plasma the discharge current and power density should be very 
high. Pressure of electrically conductive gas to develop a plasma is about 105 Pa, and 
temperature T > 8000 K [38]. 
 
                          
                                     Figure 2.10: Atmospheric Arc Plasma System 
2.6.2.2 Vacuum arc plasma source 
 
Vacuum arc plasma source includes two parts such as plasma production unit and 
macro-particle filter like in Figure 2.11 [38]. If a high voltage is applied, arc 
discharge between the cathode and anode is started. The arc discharge current is 
located at the cathode surface which forms non-stationary locations of extremely 
high current density. High density current occurs because of high power density that 
result in a phase transformation from solid cathode material to ionized plasma. 
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Figure 2.11: Vacuum Arc Plasma System 
 
2.6.2.3 Laser plasma source 
 
In the Laser Plasma Source, the plasma is generated by interactions between high-density 
laser pulses and the solid as shown Figure 2.12 [38].  
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                   Figure 2.12: Laser Plasma System 
 
2.6.3 RF plasma treatment 
 
2.6.3.1 Surface  modification 
 
Surface modification of polymers by plasma treatment is achieved using gases such 
as H2, O2, N2, argon and helium [38]. When plasma treatment to a surface is applied, 
enhanced adhesion ability, and surface wettability, and reduced surface friction can 
be achieved. Furthermore, removal of surface contaminants and weakly bound 
polymer 
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layers, etching and substitution of chemical groups on the surface that permit 
covalent bonding can also achieved by plasma treatment.  
 
Removal of surface contaminants  
 
To clean polymer surfaces from contaminants such as air pollutants, fingerprints, 
oxide layers, weakly bonded surface layers and other surface additives, low-pressure 
plasma is applied to the polymer surface. The choice of gas used for contaminant 
removal depends on the nature of the contaminant and the substrate. For example, It 
is possible to remove contaminations by oxidation of organic contaminants with 
oxygen plasma or by reduction of oxides or sulphides by hydrogen plasma [43].  
 
Sputtering and etching 
 
Sputtering is removal of materials from the surface by chemical reactions and one of 
the simple methods for surface treatment. During the sputtering process, plasma is 
generated by using inert gases such as argon and neon. The ions inside the plasma 
are accelerated towards the substrate by the applied electric field. When the ions 
come into contact with the surface atoms of substrate, they make elastic and inelastic 
collisions with them, so they transfer an amount of their energies to the surface atoms. 
If the surface atoms gain the enough energy, they escape from the surface into 
vacuum chamber. Therefore, contaminations can be removed with enough sputtering 
time from surface. There are kinds of interaction between plasma and polymer, 
namely modification and degradation. If the modification dominates, the properties 
of the polymer will chance due to ion beam interaction, but if the degradation 
dominates, the polymer surface will etched off.  
 
Substitution of chemical groups 
 
Surface characteristic of polymers can be modified by using RF plasma treatment by 
substitution chemical groups that present on the surface of polymers. To modify the 
26 
 
surface different process gases can be used. These process gases may incorporate 
large varieties of chemical groups such as hydroxyl, carbonyl, carboxylic, amino or 
peroxyl groups. Gases that are used to generate plasma for substitution of chemical 
groups are reactive while inert gases are in use for plasma-induced grafting. 
 
2.6.3.2 Plasma- Induced grafting 
 
Functional groups and reactive sites are needed for RF plasma-induced grafting. 
Firstly, free radicals are formed by using inert gases, and then monomers are 
introduced on to these reactive sites to form grafted polymer. In plasma-induced 
grafting, material is added into the backbone of polymer instead of functionally 
modifying it. 
 
2.6.3.3 Plasma polymerization 
 
In plasma polymerization, gases used for plasma are the monomers for 
polymerization, so gases in the plasma undergo polymerization through a free-radical 
initiation process. Methane, ethylene, propylene, fluorocarbon monomers and 
organosilicon compounds can be polymerized by this method. In Table 2.5, some of 
the gases used for plasma and polymerization is given with their applications. 
 
Table 2.5: Plasma Gases and Applications [38] 
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3. MATERIALS & METHODS 
 
This study includes two parts. In the first part, functional groups (amino groups) 
were obtained on PTFE surfaces for hirudin immobilization by plasma induced 
grafting. To do that, optimum conditions for H2 and Ar plasma treatment were 
determined by examining the effect of power, time and pressure of the plasma 
conditions. After the optimum conditions for plasma treatment was determined, 
acrylamide monomers were used for grafting. Furthermore, to see the effect of 
plasma treatment on the PTFE surfaces, surface characterization of treated PTFE 
samples were done by water contact angle measurements, and ATR-FTIR analysis. 
 
 In the second part, hirudin was immobilized onto the created amide groups by using 
EDC/NHS technique, and finally, activity of immobilized hirudin was tested by 
using thrombogenicity (Kinetic model) assay. 
 
3.1 Materials and Laboratory Equipment 
 
3.1.1 Equipment 
The laboratory equipment used during this study is listed in Appendix A. 
3.1.2 Chemicals, enzymes, and buffers 
The chemicals, enzymes and PTFE are given in Appendix B together with their 
suppliers. The compositions and preparation of buffers and solutions are given in 
Appendix C. 
28 
 
3.2 Methods 
3.2.1 Sample preparation 
Firstly, PTFE samples (thickness: 0.025mm) were cut into square pieces (2.5 x 2.5 
cm), and then they were incubated in acetone for 24 hours at room temperature to 
remove contaminants from the surface. 
3.2.2 Optimization of plasma conditions 
Effect of power, time and pressure of the hydrogen plasma treatment, and argon 
plasma treatment on the surface characteristic of PTFE was investigated by water 
contact angle measurements and ATR-FTIR analysis. RF power was set to 25, 50, 
75,100 and 125 W, time were set to 1,2,5,8 and 12 min, and pressure was set to 
5,11,13,21 and 45 Pa for H2 plasma optimization by changing only one parameter 
while keeping others constant. Optimization of the argon plasma treatment on PTFE 
surfaces were also done by applying the same conditions used for H2 plasma. To 
determine the effect of plasma on the surface characteristic of PTFE, water contact 
angle measurements and ATR-FTR analysis were done. 
3.2.3 Contact angle measurements 
To understand the effect of plasma on hydrophilicity of PTFE surfaces, water contact 
angle measurements were done by using distilled water. The water was dropped onto 
three different regions of surface and then angles were averaged. 
3.2.4 Functional group (amino group) formation  
To obtain amino groups on the surface of prepared PTFE samples, samples were 
firstly exposed to hydrogen plasma treatment. RF glow discharge plasma source was 
used for   plasma generation. Hydrogen plasma treated samples then exposed to air 
for peroxide formation (2-2.5 h). Acrylamide solution (25% w/v; in ethanol/acetone 
(50 % v/v)) was then applied to the surface. Then, PTFE samples were dried at 37 ̊C 
for 30 minutes. Dried samples were subjected to argon plasma treatment for 
monomer grafting to form functional groups.  Finally, samples were washed in 
distilled water at 37  ̊C on a shaker for 17-18 hours to remove unbound chemicals. 
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3.2.5 ATR-FTIR analysis 
To check if there exists any new functional group on the surface of treated PTFE to 
be used hirudin immobilization, ATR-FTIR analysis were done.  Groups on the 
surface of pristine PTFE and treated PTFE were compared. 
3.2.6 Hirudin immobilization      
To immobilize hirudin on amino groups on the PTFE samples, EDC-NHS activation 
was used. This is a well known method for the attachment of carboxyl groups to 
amino groups. To do this, 5µl of NHS (0.19 mM) solution, 20.5 µl of EDC (0.38 mM) 
solution are dissolved in 5 ml of MES buffer. Hirudin (626 ATU) was added into the 
mixture. Prepared enzyme solution was then put onto the treated PTFE surface and 
incubated overnight at 4 ̊C by gently mixing on orbital shaker (50 rpm) for 
immobilization. Finally, hirudin immobilized PTFE surfaces washed with PBS buffer 
(0.1 M, pH: 7.4) for 5 hours at 4  ̊C on orbital shaker to remove excess and unbound 
enzymes. 
3.2.7. Effect of enzyme concentration 
To determine the enzyme concentration that is enough to prevent clot formation in a 
particular area, we tried different enzyme concentration (156, 313, 625 ATUs). 
Thrombogenicity test procedure was applied to these measurements and effects of 
different enzyme concentrations on clot formation were analyzed. 
3.2.8 Thrombogenicity test 
To measure the activity of immobilized hirudin, a thrombogenicity test that is also 
called as Kinetic Model was used [44]. Acid Citrate Dextrose (Appendix C, ACD, 
170 µl) solution added into 1.6 ml of fresh human blood. Three PTFE sample 
prepared for the thrombogenicity test. The first one was pristine PTFE (Control 1), 
the second one was plasma treated PTFE (Control 2), and third one was plasma 
treated and enzyme immobilized PTFE. Firstly, these samples were weighted and put 
into NaCl solution for 30 minutes at room temperature. Then 200 µl of blood-ACD 
solution was put onto the PTFE samples. To start clot formation, 20 µl of CaCl2 (0.1 
M) solution was added to each sample and mixed. 
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After 1 hour of incubation, 5 ml of distilled water put to end the clot formation. The 
clot formation was fixed with formaldehyde solution (5 ml, 37 %) with a 5 min. 
incubation. Finally, samples were washed with distilled water, dried between tissue 
paper and weighted.  
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4. RESULTS AND DISCUSSION 
4.1 Plasma Optimization and Contact Angle Measurements 
Wettability and adhesion ability of PTFE surfaces can be increased by the plasma 
treatment. This is important because adsorption of acrylamide solution on the surface 
of PTFE is essential for functional group formation. Therefore, hydrophilicity of 
surface, solubility of monomer in a solvent, and solvent adsorption by PTFE surface 
are all important and should be optimized maximum for enhanced functional group 
formation to immobilize enzymes, proteins etc. 
In our study, we examined the power, time and pressure effect on the plasma, and 
how hydrophilicity of PTFE surfaces is affected by these conditions by means of 
water contact angle measurements. Pristine PTFE has a hydrophobic character which 
is proved with our measurement as given Table 4.1.  
Table 4.1: Contact Angle of Pristine PTFE 
                                                                                                       Contact Angle(  ̊) 
 
Left Right Average 
1. Measurement 136,87 135,15 136,01 
2. Measurement 126,03 124,58 125,30 
3. Measurement 118,72 120,53 119,62 
  
Average 126,98 
 
 
The changes in the hydrophilicity of PTFE surfaces depending on the change in the 
power, time, and pressure of H2 plasma treatment are given Table 4.2, Table 4.3, and 
Table 4.4, respectively. 
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Table 4.2: Change in Contact Angle Depending on Power (H2 Plasma)    
Pressure=13 Pa,  t=1 min                                                               Contact Angle(  ̊)        
Power Left Right             Average 
25 watt 80,91 79,69 80,30 
50 watt 82,61 82,90 82,76 
75 watt 71,61 72,46 72,04 
100 watt 59,69 60,91 60,30 
125 watt 58,75 58,92 58,83 
 
Table 4.3: Change in Contact Angle Depending on Time (H2 Plasma)    
Pressure=13 Pa, Power= 125 Watt                                                Contact Angle(  ̊)   
Time Left Right             Average 
1 min 82,61 82,90 82,76 
2 min 63,19 61,88 62,54 
3 min 57,27 55,65 56,46 
5 min 63,47 62,89 63,18 
12 min 63,02  62,21 62,62 
 
Table 4.4: Change in Contact Angle Depending on Pressure (H2 Plasma)    
Power=125 W, t=2 min         Contact Angle(  ̊)   
Pressure                 Left   Right          Average 
5.1 Pa               63,47   64,55          64,01 
11 Pa               63,19   61,88  62,54 
13 Pa               60,27   58,12 59,20 
21 Pa               61,23   62,00 61,62 
45 Pa               89,74    87,12 88,43 
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These results clearly show us that there is a serious change in the water contact angle 
of H2 plasma treated PTFE surfaces. Power, time and pressure are important 
parameters of plasma treatment and play an important role on the hydrophilicity of 
PTFE. In H2 plasma treatment, hydrophilicity of surface increases depending on the 
increase in power (Figure 4.1). At 125 W, contact angle decreased from ca 127  ̊ to 
ca 59  ̊ compared to pristine PTFE. 
 
Figure 4.1: Power- Contact Angle Relation in H2 Plasma Treatment 
Time is another parameter that affects the plasma treatment results, so the 
hydrophilicity of the surface. After, optimum condition for power was set to 125 W 
in H2 plasma treatment, the effect of time was investigated at a time interval of 1-12 
min. It was seen that, 2-3 min of plasma treatment is enough and, there is no notable 
changes afterwards (Figure 4.2) .At t=2-3 min. contact angle was found to be 
between 56-62  ̊. 
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Figure 4.2: Time - Contact Angle Relation in H2 Plasma Treatment 
When the effect of Plasma pressure on the hydrophilicity was examined, it was seen 
that ca 13 Pa is the most useful range for plasma treatment. Hydrophilicity increases 
until 13 Pa then it starts to decrease again (Figure 4.3). 
 
Figure 4.3: Pressure - Contact Angle Relation in H2 Plasma Treatment 
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The most hydrophilic surface with H2 plasma was obtained at 125 W, 2 min, and 13 
Pa (=6.1 sccm). All PTFE samples were first treated in these optimum conditions   
for hirudin immobilization.  
Then conditions for Ar plasma treatment, which was used for graft polymerization, 
were optimized.  Power, time and pressure effects were given Table 4.5, Table 4.6, 
and Table 4.7, respectively. 
  Table 4.5: Change in Contact Angle Depending on Power (Ar Plasma)    
Pressure=26 Pa, t=5 min      Contact Angle(   ̊)   
Power Left Right             Average 
25 watt 73,98 73,55 73,77 
50 watt 64,45 63,09 63,77 
75 watt 83,24 82,11 82,68 
100 watt 93,27 93,48 93,38 
125 watt 110,77 110,37 110,57 
    
Table 4.6: Change in Contact Angle Depending on Time (Ar Plasma)    
Pressure=26 Pa, Power=50 watt                                            Contact Angle(  ̊)   
Time Left Right            Average 
1 min 71,12 72,87 72,00 
2 min 68,3 69,02   68,66 
5 min 64,45 63,09 63,77 
8 min 64,56 62,23 63,40 
12 min 65,19 66,31 65,75 
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Table 4.7: Change in Contact Angle Depending on Pressure (Ar Plasma) 
Power=50 W, t=2 min Contact Angle(  ̊)   
Pressure     Left                Right             Average 
10 pascal 52,96 53,51 53,24 
26 pascal    69,38 69,80 69,59 
30 pascal 71,48 70,87 71,17 
 
Optimum plasma conditions of Ar plasma was found to be similar  to that of  H2  
plasma except for power. Effect of time (Figure 4.4), and pressure effect (Figure 4.5) 
is almost the same. An increase in pressure, causes a decrease in mean free path, 
velocity, and energy of atoms and electrons, so hydrophilicity decreases in high 
pressures. However any increase in power above 50 W (Figure 4.6) results in a 
decrease in hydrophilicity in Argon plasma treatment. This is probably due to the 
inert nature of Argon. it increases surface roughness with increasing power. On the 
other hand, Hydrogen is a reactive gas and modify surface with substitution, so does 
not affect roughness as in the case of Argon plasma.   
   
                 Figure 4.4: Time - Contact Angle Relation in Ar Plasma Treatment 
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Figure 4.5: Pressure - Contact Angle Relation in Ar Plasma Treatment 
 
 
Figure 4.6: Power - Contact Angle Relation in Ar Plasma Treatment 
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In our study optimum conditions for Argon plasma induced grafting was determined 
as accepted as 50 W, 1 min, and 13 Pa. These results are consistent with the literature 
[45].  
4.2 Functional Group Formation and ATR-FTIR Analysis 
Since H2 is a reactive gas, it results in substitution of florine atoms by hydrogen. 
Then, treated surface was exposed to air and peroxides (R-O-O-R'), and 
hydroperoxides (R-O-O-H) were formed mainly by the reaction of water in the air 
with the broken bonds (free radicals) on the surface after plasma treatment (Figure 
4.7).  
 
 
Figure 4.7: Peroxide (R-O-O-R') and Hydroperoxide Formation (R-O-O-H) 
To introduce amino groups to the surface, acrylamide solution (25% w/v; in 
ethanol/acetone (50 % v/v)) was put on the surface and adsorbed by PTFE surfaces. 
Ar plasma treatment was then applied in the optimum conditions set in Section 4.2 
and unbound acrylamide was washed away. Presence of new functional groups at the 
surface of PTFE was analyzed by ATR-FTIR spectra (Figure 4.8). 
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Figure 4.8: ATR-FTIR Analysis  
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As it can be observed from the FTIR results there is a new peak at ca 1665 cm-1 
which corresponds to amide groups (O=C–NH2). Therefore, it can be said that 
functional group formation for enzyme immobilization was successfully achieved.  
There are important points to obtain functional amino groups on the surface. 
Selection of  solvent is one of them; the solvent must be able to solve  
monomers(acrylamide in our case) with high efficiency, and at the same time, it 
should be adsorbed by polymer(PTFE in our case) sufficiently. When water, which is 
one of the greatest solvent of acrylamide, was used as solvent, acrylamide grafting 
was not successful, because adsorption of water by PTFE is not good as acetone and 
ethanol as mentioned in [46]. When aqueous acrylamide solution was put on PTFE 
surface, they tend to accumulate in an area or form separate droplets but did not 
spread evenly on the surface. This affected the yield of polymer grafting. When 
Ethanol/Acetone mixture started to be used, it was observed that the monomer 
solution could spread evenly on PTFE surface and gave better results. Another thing 
to be considered is the air exposure step after the H2 plasma treatment. If acrylamide 
is directly put on the surface without air exposure, acrylamide grafting can not be 
done successfully. Hydroperoxide formation due to air exposure is crucial before 
proceeding to the next step. This finding is consistent with the literature [47].   
4.3 Thrombogenicity Test 
In thrombogenicity test, two controls were selected, pristine PTFE (Control 1) and 
plasma treated PTFE (without any protein, Control 2) and the results were presented 
in Figure 4.9 and Figure 4.10.In the case of pristine PTFE, there was a problem 
originated from the high hydrophobicity of PTFE. Blood did not spread over the 
surface, so clot formation occurs only where it is put (Figure 4.9a). There is clot 
formation in large area of plasma treated PTFE (Control 2) compared with the 
pristine PTFE. As plasma treated PTFE is hydrophilic, blood was adsorbed by PTFE 
and spread to a larger area. We observed that there is a big decrease in the clot 
formation on the hirudin immobilized PTFE surfaces.   
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             Control 1                           Control 2                  hirudin immobilized PTFE  
 
 
 
 
 
 
 
  
            Control 1                              Control 2                hirudin immobilized PTFE       
Figure 4.9: Thrombogenicity test 1(a) before coagulation starts (b) after the coagulation 
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Different enzyme concentrations resulted in different amounts of clot formation. In 
Table 4.8,  weight difference on PTFE samples depending on different enzyme 
concentrations were given.  
Table 4.8: Change in Clot Formation Depending on Enzyme Amount 
15 µl Enzyme Solution(156 ATUs)       
(60 min) initial  weight(mg) last weight (mg) Difference (mg) 
Plasma Treated PTFE 22,50         93,30    70,80 
Enzyme Immobilized PTFE 22,80       106,80 84,00 
30 µl Enzyme Solution(313 ATUs)       
(60 min) initial weight(mg) last weight (mg) Difference (mg) 
Plasma Treated PTFE 23,50 106,90 83,40 
Enzyme Immobilized PTFE 26,60         68,30          41,70 
60 µl Enzyme Solution(626 ATUs)       
(60 min) initial weight(mg) last weight (mg) Difference (mg) 
Plasma Treated PTFE 22,80     107,30 84,50 
Enzyme Immobilized PTFE 25,50           51,50 26,00 
 
 
These results showed that 60 µl enzyme solution (626 ATUs) is more efficient to 
prevent clot formation than 30 µl (313 ATUs) and 15 µl (156 ATUs) of enzyme 
solution did not show any antithrombogenicity effect when compared with the 
control on a 2.5 cm2 surface area. Depending on the increase in enzyme, clot 
formation decreases like in Figure 4.10.  
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Figure 4.10: Weight Change versus Enzyme Amount 
 
While there is a big decrease in weight difference, which occurs because of clot 
formation, with the increased enzyme amount from 125 to 626 ATUs, decrease in 
weight difference slows down after ca 400 ATUs which mean we were almost 
reached to suitable enzyme amount for a 2.5 cm2 surface area.   
After determination of suitable enzyme amount, we repeated our experiments and 
checked the reproducibility of experiments. In the most of these experiments, we 
observed that there is a big decrease in the weight of PTFE samples   which are 
enzyme immobilized compared with the pristine or just plasma treated PTFE samples.  
Even in some cases, there is no clot formation like in Figure 4.11. 
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  hirudin immobilized PTFE                                                              Control 2                               
 
Figure 4.11: Thrombogenicity test 2
 
1 
  hour 
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Antithrombogenic activity of immobilized hirudin can be clearly seen in Figures 4.9 
and 4.11. The result was obtained in Figure 4.9 were taken before optimization of the 
procedure, but even these results show the difference between hirudin immobilized 
PTFE and controls. There are many reasons why some clot formation occurred in 
previous tests (Figure 4.9) compared with the later results (Figure 4.11):  
• It is sometimes difficult to set the plasma conditions to optimum values and 
this can affect the properties and monomer grafting. Therefore, the surface 
should be checked by FTIR and water contact angle tests before protein 
immobilization study. 
• At the beginning of the experiments distilled water with pH 5.5 was used for 
enzyme immobilization. EDC-NHS immobilization is best done at pH 5.5 
and adversely affected by buffers. Then MES buffer which is suitable for this 
reaction to take place was obtained and started to be used in the experiments. 
It is possible that enzyme immobilization yield is increased by MES buffer 
usage. 
•  As It can be seen from Figure 4.9, clot formation generally occurs at the 
interface of hydrophobic and hydrophilic regions. Coagulation factors may 
assemble easier in these region and the clot formation is more likely.  
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5.CONCLUSION   
PTFE is an attractive material for biomedical applications, and especially for 
vascular grafts, catheters etc. This is due to its high inertness, good mechanical 
properties and high oxygen permeability which are crucial for this type of 
applications. But the surface properties of PTFE is not very suitable to be used as it is. 
In catheters, for example, when pristine PTFE is used, an antithrombogenic agent 
should be given to the patient to prevent surface induced blood coagulation. In 
vascular grafts, pristine PTFE may lead to surface induced thrombosis and failure of 
the graft. The aim of this thesis is to increase the blood compatibility of PTFE to 
improve its performance as a blood-contacting biomaterial. For this, first the 
acrylamide grafting via plasma treatment was optimized, then hirudin, a potent 
antithrombogenci protein, was immobilized on the surface. 
Firstly, the effect of power, time and pressure of plasma treatment on the surface 
modification, thus hydrophilicity of PTFE was determined. Parameters for H2 plasma 
and Argon plasma gave similar results except for power. When power value exceed 
50 W in Argon plasma, a decrease in hydrophilicity was observed as opposed to H2 
plasma treatment. A serious decrease in water contact angle of PTFE surfaces can be 
obtained by optimizing the hydrogen plasma treatment conditions. Water contact 
angle can be further down by monomer grafting. Solvent is found to be an important 
parameter for monomer grafting because a good solvent may solve a large amount of 
acrylamide, but if it is not adsorbed by PTFE efficiently, monomer grafting severely 
reduced. Hirudin, a good antithrombogenic agent, was successfully immobilized on 
PTFE surface by EDC/NHS activation. To measure the activity of immobilized 
hirudin, thrombogenicity (Kinetic Model) test was applied and it was seen that 
immobilized hirudin retain its activity after immobilization. 
As a result, we increased blood compatibility of PTFE surfaces by plasma-induced 
monomer grafting and hirudin immobilization. This material should now be tested in 
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animal models to have a better idea about its potential in medical applications such 
as vascular graft, catheters etc.   
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Appendix A 
Laboratory Equipment 
 
Pipettes            Eppendorf  10 µL 100 µl, 1000 µl, 2500 µl 
pH meter            Mettler Toledo MP220 
Pure water systems                                  USF Elga UHQ-PS-MK3, Elga Labwater 
Shaker (37  ̊C)                                           Certomat S II 
Orbital Shaker (4  ̊ C)                              Heidolph Duomax 1030             
RF Power Generator                               PFG COOE/Hüttinger 
Vacuum Equipment                                TSY-HF450/PECVD350/MMPS20/C 
                                                                   Genertec International Corporation 
Contact Angel                                          Cam200 KSV 
ATR-FTIR                                                NICOLET 6700 
Balances                                                    Precisa XB220A 
                                                                   Precisa BJ610C 
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Appendix B 
Chemicals 
Ethanol                                                                                          Sigma-Aldrich 
Acetone                                                                                          Sigma-Aldrich 
Acrylamide                                                                             Sigma-Aldrich 
N-Hydroxysuccinimide                                                                Sigma-Aldrich 
N-(3-Dimethylaminogrouply)-N-ethly-carbodiimide                Sigma-Aldrich 
NaOH                                                                                             Riedel-de Haën 
NaH2PO4.2H2O                                                                             Sigma-Aldrich 
Na2HPO4.2H2O                                                                             J.T. Baker 
 C6H8O7 .H2O                                                                                Sigma-Aldrich 
Na3C6H5O7 . 2H2O                                                                        LaCheMa 
C6H12O6                                                                                                          Sigma-Aldrich                             
NaCl                                                                                               Carlo Erba Reagent 
CaCl2.2H2O                                                                                   MERCK 
CH2O                                                                                              J.T.Baker 
C6H13NO4S.H2O                                                                            Sigma-Aldrich 
 
ENZYMES AND PTFE 
rHirudin                                     Sigma-Aldrich 
Polytetrafluoroethylene (PTFE)                                                  Sigma-Aldrich       
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Appendix C 
Solutions and Buffers 
 
Acrylamide Solution (% 25 w/v, %50 v/v Ethanol/Acetone)(30 ml) 
 
• 15 ml                          Ethanol 
• 15 ml                          Acetone 
• 7.5 gr                          Acrylamide 
 
N-Hydroxysuccinimide NHS  Solution (5 ml) 
 
• 5 ml                            Distill Water 
• 5.4 mgr                        NHS                            
 
2-(N-morpholino)ethanesulfonic acid (MES) Buffer (0.05 M) (pH:5.5) (400 ml) 
 
• 3.90 gr                        MES Buffer 
• 400 ml                        Distill Water 
• 0.1 M                          NaOH Solution 
 
- Add NaOH solution until pH reaches to 5.5          
 
Phosphate Buffer Saline (PBS) Buffer (1 M) (pH: 7.39) (100 ml) 
 
• 0.416 gr                      NaH2PO4.2H2O 
• 1.25   gr                      Na2HPO4.2H2O 
• 0.85   gr                      NaCl 
• 100   ml                      Distill Water 
 
-  To obtain 10 ml, 0.1 M PBS, add 9 ml of distill water to 1 ml of 1 M PBS buffer.
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rHirudin Stock Solution (60 µl)(626 ATU) 
 
• Add 1ml of 0.1 M PBS buffer  into the rHirudin bottle (104378 ATU) 
•  Take 350 µl of rhirudin solution (36571 ATU) from bottle 
• Divide 350 µl of rhirudin solution (36571 ATU) into eppendorfs? that contain 
60 µl of rhirudin solution (626 ATU) 
•  Save both the main stock of 650 µl and 60 µl rhirudin solutions at (-20  ̊C)   
 
Acid Citrate Dextrose (ACD) Solution (75 ml) 
 
• 0.59         gr                                C6H8O7 .H2O 
• 1.65         gr                                Na3C6H5O7 . 2H2O 
• 1.84         gr                                C6H12O6 
• 75           ml                                 Distill Water 
 
Sodium Chloride (NaCl) Solution (30 ml) (% 0.5) 
 
• 0.15        gr                                  NaCl 
• 30          ml                                  Distill Water   
 
Calcium Chloride (CaCl2) Solution (0.1 M) (30 ml) 
• 0.44       gr                                  CaCl2.2H2O  
• 30          ml                                 Distill Water 
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